Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Accounts Payables (2016 - 2025)

Cumberland Pharmaceuticals (CPIX) has disclosed Accounts Payables for 16 consecutive years, with $18.6 million as the latest value for Q4 2025.

  • Quarterly Accounts Payables rose 33.44% to $18.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $18.6 million through Dec 2025, up 33.44% year-over-year, with the annual reading at $18.6 million for FY2025, 33.44% up from the prior year.
  • Accounts Payables hit $18.6 million in Q4 2025 for Cumberland Pharmaceuticals, up from $13.8 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $18.6 million in Q4 2025 to a low of $9.0 million in Q2 2021.
  • Historically, Accounts Payables has averaged $12.0 million across 5 years, with a median of $11.5 million in 2022.
  • Biggest five-year swings in Accounts Payables: fell 28.03% in 2021 and later soared 33.44% in 2025.
  • Year by year, Accounts Payables stood at $9.6 million in 2021, then rose by 12.22% to $10.8 million in 2022, then grew by 29.75% to $14.0 million in 2023, then dropped by 0.88% to $13.9 million in 2024, then skyrocketed by 33.44% to $18.6 million in 2025.
  • Business Quant data shows Accounts Payables for CPIX at $18.6 million in Q4 2025, $13.8 million in Q3 2025, and $13.4 million in Q2 2025.